CN103450312A - 维库溴铵的新晶型及其制备方法和用途 - Google Patents
维库溴铵的新晶型及其制备方法和用途 Download PDFInfo
- Publication number
- CN103450312A CN103450312A CN2012101790696A CN201210179069A CN103450312A CN 103450312 A CN103450312 A CN 103450312A CN 2012101790696 A CN2012101790696 A CN 2012101790696A CN 201210179069 A CN201210179069 A CN 201210179069A CN 103450312 A CN103450312 A CN 103450312A
- Authority
- CN
- China
- Prior art keywords
- crystal form
- vecuronium bromide
- preparation
- vecuronium
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960004298 vecuronium bromide Drugs 0.000 title claims abstract description 120
- VEPSYABRBFXYIB-PWXDFCLTSA-M vecuronium bromide Chemical compound [Br-].N1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 VEPSYABRBFXYIB-PWXDFCLTSA-M 0.000 title claims abstract description 120
- 239000013078 crystal Substances 0.000 title claims abstract description 103
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 30
- 239000002904 solvent Substances 0.000 claims description 25
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 13
- 230000001476 alcoholic effect Effects 0.000 claims description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 238000010521 absorption reaction Methods 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 239000012046 mixed solvent Substances 0.000 claims description 6
- 239000002249 anxiolytic agent Substances 0.000 claims description 5
- 230000002999 depolarising effect Effects 0.000 claims description 5
- 230000003387 muscular Effects 0.000 claims description 5
- 238000001953 recrystallisation Methods 0.000 claims description 5
- 238000002425 crystallisation Methods 0.000 claims description 4
- 230000008025 crystallization Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 2
- 238000009835 boiling Methods 0.000 claims description 2
- 239000003610 charcoal Substances 0.000 claims description 2
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 2
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 7
- 238000002347 injection Methods 0.000 abstract description 7
- 239000007924 injection Substances 0.000 abstract description 7
- 210000004204 blood vessel Anatomy 0.000 abstract description 4
- 230000007774 longterm Effects 0.000 abstract description 4
- 238000003860 storage Methods 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract 2
- 230000000977 initiatory effect Effects 0.000 abstract 1
- 230000007794 irritation Effects 0.000 abstract 1
- 238000011031 large-scale manufacturing process Methods 0.000 abstract 1
- 230000000116 mitigating effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 32
- 238000000034 method Methods 0.000 description 22
- 239000007791 liquid phase Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000003814 drug Substances 0.000 description 8
- 238000005286 illumination Methods 0.000 description 6
- 229940090044 injection Drugs 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- -1 ammonium steroid Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000012496 blank sample Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000002695 general anesthesia Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000012905 visible particle Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 1
- GGRLKHMFMUXIOG-UHFFFAOYSA-M 2-acetyloxyethyl(trimethyl)azanium;hydroxide Chemical compound [OH-].CC(=O)OCC[N+](C)(C)C GGRLKHMFMUXIOG-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000002643 anesthesia adjuvant Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 150000001896 cresols Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940089256 fungistat Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 238000001782 photodegradation Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (15)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210179069.6A CN103450312B (zh) | 2012-06-01 | 2012-06-01 | 维库溴铵的晶型及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210179069.6A CN103450312B (zh) | 2012-06-01 | 2012-06-01 | 维库溴铵的晶型及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103450312A true CN103450312A (zh) | 2013-12-18 |
CN103450312B CN103450312B (zh) | 2015-12-02 |
Family
ID=49733190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210179069.6A Active CN103450312B (zh) | 2012-06-01 | 2012-06-01 | 维库溴铵的晶型及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103450312B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101684139A (zh) * | 2008-09-27 | 2010-03-31 | 徐州师范大学 | 维库溴铵的合成工艺 |
CN102344479A (zh) * | 2011-05-30 | 2012-02-08 | 成都苑东药业有限公司 | 一种甲基溴化铵类季铵盐的制备方法 |
CN102603850A (zh) * | 2011-09-20 | 2012-07-25 | 海南灵康制药有限公司 | 一种维库溴铵化合物及其制法 |
-
2012
- 2012-06-01 CN CN201210179069.6A patent/CN103450312B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101684139A (zh) * | 2008-09-27 | 2010-03-31 | 徐州师范大学 | 维库溴铵的合成工艺 |
CN102344479A (zh) * | 2011-05-30 | 2012-02-08 | 成都苑东药业有限公司 | 一种甲基溴化铵类季铵盐的制备方法 |
CN102603850A (zh) * | 2011-09-20 | 2012-07-25 | 海南灵康制药有限公司 | 一种维库溴铵化合物及其制法 |
Non-Patent Citations (3)
Title |
---|
KOOIJMAN,HUUB 等: "Molecular structure of vecuronium bromide, a neuromuscular blocking agent. Crystal structure, molecular mechanics and NMR investigations", 《J. CHEM. SOC. PERKIN TRANS.2》, no. 10, 31 December 1991 (1991-12-31), pages 1581 - 1586 * |
VAN DER SLUIS P. 等: "Crystallization of low-molecular-weight organic compounds for x-ray crystallography", 《JOURNAL OF APPLIED CRYSTALLOGRAPHY》, vol. 22, no. 4, 31 December 1989 (1989-12-31), pages 340 - 344 * |
VAN DER SLUIS, P.; KROON J.: "The development and prediction of needle habits", 《JOURNAL OF CRYSTAL GROWTH》, vol. 104, no. 2, 31 December 1990 (1990-12-31), pages 310 - 314, XP024437857, DOI: doi:10.1016/0022-0248(90)90131-4 * |
Also Published As
Publication number | Publication date |
---|---|
CN103450312B (zh) | 2015-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105579034B (zh) | 一种gabaa受体增强剂用于制备镇静麻醉的药物中的用途 | |
JPH0761941B2 (ja) | 鎮痛作用を有する沸騰組成物 | |
CN101987094B (zh) | 门冬氨酸鸟氨酸注射液及其制备方法 | |
CN102964403A (zh) | 天麻素化合物及其药物组合物 | |
CN102336801A (zh) | 醋酸阿比特龙多晶型物和药用组合物 | |
CN104447904B (zh) | 一种口服生物利用度高的稳定天麻素晶体及其制备方法、制剂与应用 | |
CN102099334A (zh) | 作为蕈毒碱受体拮抗剂的新颖化合物 | |
CN108926564A (zh) | 一种非去极化肌松剂组合物及其制备方法和用途 | |
CN103145713A (zh) | 一种多索茶碱结晶化合物及其冻干粉针 | |
TWI326684B (zh) | ||
CN117547534A (zh) | 尼可地尔缓释制剂及其制备方法 | |
CN103450312B (zh) | 维库溴铵的晶型及其制备方法和用途 | |
CN101632646B (zh) | 一种盐酸奥洛他定片及其制备方法和检测方法 | |
CN103450311B (zh) | 维库溴铵的晶型及其制备方法和用途 | |
CN115461052B (zh) | Arb代谢产物与nep抑制剂的复合物预防和/或治疗肾病的药物用途 | |
CN100475260C (zh) | 草豆蔻提取物及其制备 | |
CN104059082B (zh) | 硝基咪唑杂环类化合物及其在制备治疗结核病药物中的应用 | |
CN101874792A (zh) | 间苯三酚口腔崩解片及其制备方法 | |
CN110128429A (zh) | 一种西地那非-安赛蜜盐型及其制备方法和用途 | |
CN109432440A (zh) | 一种吡喹酮羟丙基环糊精包合物及其制备方法和应用 | |
CN103025705B (zh) | 4-甲基苯甲酸4-[2-二甲基胺基-1-(1-羟基环己基)乙基]苯酯盐酸盐的多晶型物、制备方法及其应用 | |
CN102091240B (zh) | 一种大川芎方微乳鼻腔给药制剂及其制备方法与应用 | |
CN102424653B (zh) | 非诺贝特化合物及其阿托伐他汀钙非诺贝特药用组合物 | |
CN106854190A (zh) | 一种新的炎琥宁化合物及其药物组合物 | |
WO2020073844A1 (zh) | 一种有效成分包含银杏萜内酯的滴丸及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 646100 Industrial Park, Fu Zhen Town, Luzhou, Sichuan, Luxian County Patentee after: Luzhou kered Pharmaceutical Co.,Ltd. Address before: 646106 Industrial Park, Fu Zhen Town, Luzhou, Sichuan, Luxian County Patentee before: SICHUAN CREDIT CHEMWERTH PHARMACEUTICAL Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 646100 Industrial Park, Fu Zhen Town, Luzhou, Sichuan, Luxian County Patentee after: Sichuan Tiandao Pharmaceutical Co.,Ltd. Country or region after: China Address before: 646100 Industrial Park, Fu Zhen Town, Luzhou, Sichuan, Luxian County Patentee before: Luzhou kered Pharmaceutical Co.,Ltd. Country or region before: China |